AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16273784 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 12017351 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate 10 mg as a 5-minute i.v. infusion
Number of subjects: 8
Study 10190915 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP), 400 microgram/d
Number of subjects: 333
Study 10190915 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (BUD), 800 microgram/d
Number of subjects: 333
Study 10190915 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 333
Study 10190915 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (BUD)
Number of subjects: 333
Study 7779558 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (240 micrograms of organic selenium/day)
Number of subjects: 24
Study 7779558 — intervention group
Group type: COMPARATOR
Intervention: Placebo (imaginary supplementation)
Number of subjects: 24
Study 2323246 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography within 24 hours of admission
Number of subjects: 196
Study 2323246 — intervention group
Group type: COMPARATOR
Intervention: Control (no echocardiography)
Number of subjects: 196
Study 371056 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg salbutamol solution
Number of subjects: 9
Study 371056 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg salbutamol solution
Number of subjects: 9
Study 371056 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg salbutamol solution
Number of subjects: 9
Study 31227390 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA + estrogen replacement (ERT) - oral micronized DHEA 50 mg + 20 mcg ethinyl estradiol/.1 mg levonorgestrel daily (n = 35)
Number of subjects: 70
Study 31227390 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 35)
Number of subjects: 70
Study 31227390 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA + ERT
Number of subjects: 70
Study 31227390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 27541287 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT), progressive RT for 12 weeks, eight exercises, three sets of 10-15 repetitions maximum, three times per week
Number of subjects: 41
Study 27541287 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG), no exercise during the intervention period
Number of subjects: 41
Study 25873250 — intervention group
Group type: EXPERIMENTAL
Intervention: Current weekend allied health services
Number of subjects: 6
Study 25873250 — intervention group
Group type: EXPERIMENTAL
Intervention: New stakeholder-driven model of weekend allied health service delivery
Number of subjects: 6
Study 25873250 — intervention group
Group type: COMPARATOR
Intervention: No weekend allied health services
Number of subjects: 6
Study 23435526 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-coated sutures
Number of subjects: 374
Study 23435526 — intervention group
Group type: COMPARATOR
Intervention: Control group (identical sutures without triclosan)
Number of subjects: 374
Study 20624287 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatments (specific treatments not detailed)
Number of subjects: 25
Study 20624287 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-inferiority studies
Number of subjects: 25
Study 20624287 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind trials
Number of subjects: 25
Study 20624287 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention-to-treat analysis
Number of subjects: 25
Study 20624287 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective outcome reporting
Number of subjects: 25
Study 18922851 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA (thoracic epidural anaesthesia)
Number of subjects: 54
Study 18922851 — intervention group
Group type: COMPARATOR
Intervention: TEA (systemic opioids)
Number of subjects: 54
Study 15984917 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based video CBT
Number of subjects: 36
Study 15984917 — intervention group
Group type: COMPARATOR
Intervention: Classroom CBT or no treatment (control)
Number of subjects: 36
Study 12660387 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) for one month
Number of subjects: 24
Study 12660387 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 24
Study 10674505 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia
Number of subjects: 28
Study 10674505 — intervention group
Group type: COMPARATOR
Intervention: Halothane anesthesia
Number of subjects: 28
Study 10674505 — intervention group
Group type: EXPERIMENTAL
Intervention: Both anesthetics
Number of subjects: 28
Study 8911385 — intervention group
Group type: EXPERIMENTAL
Intervention: LoFric catheter
Number of subjects: 33
Study 8911385 — intervention group
Group type: COMPARATOR
Intervention: Mentor catheter
Number of subjects: 33
Study 1867345 — intervention group
Group type: COMPARATOR
Intervention: Single dose of ivermectin (150 micrograms/kg)
Number of subjects: 0
Study 1867345 — intervention group
Group type: COMPARATOR
Intervention: Four doses of ivermectin (150 micrograms/kg) at 6-month intervals
Number of subjects: 0
Study 6354826 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (400 and 800 mg/day)
Number of subjects: 0
Study 6354826 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (375 and 750 mg/day)
Number of subjects: 0
Study 6354826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6354826 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (800 mg/day)
Number of subjects: 0
Study 6354826 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chenodeoxycholic acid groups
Number of subjects: 0
Study 6354826 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid and Ursodeoxycholic acid (800 mg)
Number of subjects: 0
Study 6354826 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Number of subjects: 0
Study 31977517 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution
Number of subjects: 8616
Study 31977517 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 8616
Study 29728334 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil (2 μg by intracoronary infusion)
Number of subjects: 57
Study 29728334 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (200 μg)
Number of subjects: 57
Study 26889616 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous RF heat lesion at the lateral branches of S1, S2, S3, and S4 nerve roots and the posterior ramus dorsalis of L5
Number of subjects: 60
Study 26889616 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (same as treatment group except for the RF heat lesion)
Number of subjects: 60
Study 25241364 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dydrogesterone treatment during early pregnancy
Number of subjects: 0
Study 25241364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23788684 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid infusion
Number of subjects: 92
Study 23788684 — intervention group
Group type: COMPARATOR
Intervention: Denosumab injection
Number of subjects: 92
Study 20921216 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training for 6 months
Number of subjects: 53
Study 20921216 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training cessation (2 weeks after training)
Number of subjects: 53
Study 19022156 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (3‐hydroxy‐3‐methyl‐glutaryl‐CoA reductase inhibitors)
Number of subjects: 63899
Study 16608809 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate radiological investigation
Number of subjects: 172
Study 16608809 — intervention group
Group type: COMPARATOR
Intervention: Deferred radiological investigation
Number of subjects: 172
Study 14582813 — intervention group
Group type: EXPERIMENTAL
Intervention: Particulate matter less than or equal to 2.5 microm (PM2.5)
Number of subjects: 133
Study 14582813 — intervention group
Group type: EXPERIMENTAL
Intervention: Particulate matter less than or equal to 10 microm (PM10)
Number of subjects: 133
Study 11032464 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (400-1200 mg/d)
Number of subjects: 199
Study 11032464 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (10-30 mg/d)
Number of subjects: 199
Study 11032464 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 199
Study 11032464 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 199
Study 9156546 — intervention group
Group type: EXPERIMENTAL
Intervention: School-Based Adolescent Health Care Program
Number of subjects: 19
Study 9156546 — intervention group
Group type: COMPARATOR
Intervention: Control group (national sample of urban youths)
Number of subjects: 19
Study 1940446 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose UVB exposure
Number of subjects: 0
Study 6489694 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 83
Study 30852536 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-disparate partnerships
Number of subjects: 1306
Study 30089292 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical acupuncture with oral essential amino acids (EA + AA)
Number of subjects: 48
Study 30089292 — intervention group
Group type: COMPARATOR
Intervention: Oral essential amino acids alone (AA)
Number of subjects: 48
Study 30089292 — intervention group
Group type: COMPARATOR
Intervention: Comparison between EA + AA and AA
Number of subjects: 48
Study 27091532 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep time (PSG-TST)
Number of subjects: 147
Study 27091532 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported habitual sleep duration (SR-HSD)
Number of subjects: 147
Study 25226941 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor horse riding exercise (60 min/day, 3 days/week for 8 weeks)
Number of subjects: 20
Study 21628086 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE with polyvinyl alcohol (PVA) particles 47‐90 μm (n=8)
Number of subjects: 17
Study 21628086 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE with polyvinyl alcohol (PVA) particles >90‐250 μm (n=9)
Number of subjects: 17
Study 21167033 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed choice invitation
Number of subjects: 417
Study 21167033 — intervention group
Group type: COMPARATOR
Intervention: Standard type invitation
Number of subjects: 417
Study 18068485 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (a third-generation bisphosphonate)
Number of subjects: 0
Study 18068485 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates (general)
Number of subjects: 0
Study 18068485 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical markers of bone turnover and tumor markers
Number of subjects: 0
Study 16164495 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam loading dose of 200 microg/kg
Number of subjects: 23
Study 16164495 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam maintenance dose ranging from 37.5 to 100 microg/kg/h
Number of subjects: 23
Study 15314976 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with Vepesid and Cisplatin
Number of subjects: 35
Study 15314976 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients who had not undergone inductive chemotherapy)
Number of subjects: 35
Study 10665467 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide-related words
Number of subjects: 31
Study 10665467 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 31
Study 10665467 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicidal ideation
Number of subjects: 31
Study 10665467 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures of anxiety, depression, or hopelessness
Number of subjects: 31
Study 8916629 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood Management (MM) intervention
Number of subjects: 201
Study 8916629 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE) intervention
Number of subjects: 201
Study 8916629 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Number of subjects: 201
Study 8916629 — intervention group
Group type: COMPARATOR
Intervention: 0 mg nicotine gum (placebo)
Number of subjects: 201
Study 8916629 — intervention group
Group type: EXPERIMENTAL
Intervention: History-positive participants
Number of subjects: 201
Study 8916629 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent of depression diagnosis
Number of subjects: 201
Study 8916629 — intervention group
Group type: EXPERIMENTAL
Intervention: No treatment differences
Number of subjects: 201
Study 2008293 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% hyaluronan (Healon; HYA) instilled once daily for 7 days
Number of subjects: 60
Study 2008293 — intervention group
Group type: COMPARATOR
Intervention: Sterile rice paper prosthesis
Number of subjects: 60
Study 7037155 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum immunotherapy
Number of subjects: 260
Study 7037155 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment alone (Control)
Number of subjects: 260
Study 30974433 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant replacement therapy
Number of subjects: 0
Study 30974433 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive respiratory support
Number of subjects: 0
Study 30974433 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 0
Study 30974433 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine and postnatal steroids
Number of subjects: 0
Study 30974433 — intervention group
Group type: EXPERIMENTAL
Intervention: General care protocols
Number of subjects: 0
Study 29651519 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating brackets (Damon Q, DQ)
Number of subjects: 32
Study 29651519 — intervention group
Group type: COMPARATOR
Intervention: Conventional brackets (Titanium Orthos, TO)
Number of subjects: 32
Study 27735908 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum soluble Fas ligand (sFas-L) levels measured by enzyme immunoassay in patients with poor course of CHF (n=45)
Number of subjects: 94
Study 27735908 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum soluble Fas ligand (sFas-L) levels measured by enzyme immunoassay in patients with favorable course of CHF (n=49)
Number of subjects: 94
Study 27735908 — intervention group
Group type: COMPARATOR
Intervention: Comparison of baseline sFas-L levels between CHF patients and control group
Number of subjects: 94
Study 27735908 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC analysis of sFas-L levels for cardiovascular risk stratification
Number of subjects: 94
Study 27735908 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of left ventricular (LV) ejection fraction with sFas-L concentrations
Number of subjects: 94
Study 27735908 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between serum sFas-L concentrations and LV remodeling parameters
Number of subjects: 94
Study 24222705 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing movement-measuring device (BMMD) during deep breathing (DB)
Number of subjects: 10
Study 22526603 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (measured by a four-category index)
Number of subjects: 12403
Study 22526603 — intervention group
Group type: COMPARATOR
Intervention: Inactive individuals
Number of subjects: 12403
Study 19067472 — intervention group
Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg once daily for 3 days
Number of subjects: 20
Study 19067472 — intervention group
Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg single dose
Number of subjects: 20
Study 19067472 — intervention group
Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg repeated dosing
Number of subjects: 20
Study 19067472 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study 17460560 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 140
Study 17460560 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 140
Study 16103328 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream applied 3 times a week for 16 weeks
Number of subjects: 21
Study 16103328 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied 3 times a week for 16 weeks
Number of subjects: 21
Study 12065555 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (cisplatin, vincristine, and fluorouracil)
Number of subjects: 46
Study 12065555 — intervention group
Group type: COMPARATOR
Intervention: Regimen B (cisplatin and continuous-infusion doxorubicin)
Number of subjects: 46
Study 12065555 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 46
Study 12065555 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage I patients
Number of subjects: 46
Study 12065555 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage III patients
Number of subjects: 46
Study 12065555 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IV patients
Number of subjects: 46
Study 9809084 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents' group (surgeons with less experience)
Number of subjects: 167
Study 9809084 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents' group
Number of subjects: 167
Study 9809084 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents' group (with prophylaxis for PONV)
Number of subjects: 167
Study 8770854 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 0
Study 8770854 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost per year of life saved
Number of subjects: 0
Study 8770854 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost per quality adjusted life-year
Number of subjects: 0
Study 8770854 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental cost-effectiveness of different interventions
Number of subjects: 0
Study 2533616 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin, a gonadotropin releasing hormone analog, dosage and duration not specified.
Number of subjects: 0
Study 2533616 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin
Number of subjects: 0
Study 402093 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 100
Study 402093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31830347 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF (docetaxel 60 mg/m2, cisplatin 60 mg/m2, 5-FU 750 mg/m2 continuous IV infusion)
Number of subjects: 219
Study 31830347 — intervention group
Group type: COMPARATOR
Intervention: PF (cisplatin 75 mg/m2, 5-FU 750 mg/m2)
Number of subjects: 219
Study 31830347 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF
Number of subjects: 219
Study 31830347 — intervention group
Group type: COMPARATOR
Intervention: PF
Number of subjects: 219
Study 30452084 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention (n = 669)
Number of subjects: 1341
Study 30452084 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE) intervention (n = 672)
Number of subjects: 1341
Study 30452084 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization (1-3 cumulative hospital days)
Number of subjects: 1341
Study 30452084 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization (≥4 cumulative hospital days)
Number of subjects: 1341
Study 28040350 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 100 U/mL (Gla-100)
Number of subjects: 771
Study 28040350 — intervention group
Group type: COMPARATOR
Intervention: Neutral protamine Hagedorn (NPH) insulin
Number of subjects: 771
Study 28040350 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population (all insulin regimens)
Number of subjects: 771
Study 28040350 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 771
Study 28040350 — intervention group
Group type: EXPERIMENTAL
Intervention: Gla-100 treatment
Number of subjects: 771
Study 28040350 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower baseline DTSQs
Number of subjects: 771
Study 28040350 — intervention group
Group type: EXPERIMENTAL
Intervention: Study
Number of subjects: 771
Study 28040350 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower severe hypoglycemia rate
Number of subjects: 771
Study 28040350 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline HbA1c
Number of subjects: 771
Study 26063677 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDX) 40-60 mg/day for 4 weeks
Number of subjects: 32
Study 26063677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 22772328 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 185
Study 22772328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 20619576 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI) - nurse-led decision counseling session
Number of subjects: 313
Study 20619576 — intervention group
Group type: COMPARATOR
Intervention: Standard Intervention (SI) - practice satisfaction survey
Number of subjects: 313
Study 19966380 — intervention group
Group type: EXPERIMENTAL
Intervention: De Marco Formula (DMF) 15 ml/kg .day i.m. for 10 days, then twice a week until healing or completion of 52 days
Number of subjects: 118
Study 19966380 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 118
Study 17111305 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabinoxylan (15 g)
Number of subjects: 11
Study 17111305 — intervention group
Group type: COMPARATOR
Intervention: Placebo (white bread rolls)
Number of subjects: 11
Study 14964555 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound scissors (group A)
Number of subjects: 76
Study 14964555 — intervention group
Group type: COMPARATOR
Intervention: No ultrasound scissors (group B)
Number of subjects: 76
Study 11697810 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg alendronate + 500 mg calcium (n = 8)
Number of subjects: 13
Study 11697810 — intervention group
Group type: COMPARATOR
Intervention: 500 mg calcium only (n = 5)
Number of subjects: 13